Price gouging in the pharmaceutical industry has become a common feature of health news. Who can forget Martin Shkreli’s infamous price hike of the HIV drug Daraprim, which went from USD13.50 to $750 in the summer of 2015? Are international laws tough enough to ensure that the bottom line is the people and not profit?

Produced by: Tina Carmillia

Presented by: Meera Sivasothy

Tags:  international trade,  intellectual property,  access to medicine,  patent,  price control,  compulsory license,  cancer medicine,  drug prices,  sofosbuvir,  health and living,  the bigger picture,  Healthcare, Pharma, Biotech,  Health